Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule

A composition comprising (i) a first recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein exogenous DNA encoding a tumor-associated antigen, or an immunogenic segment thereof, selected from the group consisting of oncofetal antigens, MART-1, MAGE-1, MAGE-3, gp100, tyrosinase, CEA, PSA, CA-125, erb-2, Muc-1, Muc-2, point-mutated ras, point-mutated p53 and TAG-72, and (ii) a second recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein exogenous DNA encoding B7.1 B7.2, or B7.1 and B7.2;

• wherein the composition is able to co-infect a host cell resulting in co-expression of the antigen-encoding DNA and the B7.1, B7.2, or B7.1 and B7.2-encoding DNA and further wherein the co-expression causes an enhanced cellular immune response against cells expressing tumor-associated antigen.

A composition comprising (i) a first recombinant virus comprising a recombinant virus genome, or an injectable portion thereof, having incorporated therein exogenous DNA encoding carcinoembryonic antigen (CEA), prostate specific antigen (PSA), MUC-1 antigen or an immunogenic portion thereof, and (ii) a second recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein exogenous DNA encoding B7.1, B7.2, or B7.1 and B7.2;

• wherein the composition is able to co-infect a host cell resulting in co-expression of the antigen-encoding DNA and the B7.1, B7.2, or B7.1 and B7.2-encoding DNA and further wherein the co-expression causes an enhanced cellular immune response against cells expressing the CEA, PSA or MUC-1 antigens.

A composition comprising (i) a first recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein exogenous DNA encoding a tumor-associated antigen or an immunogenic portion thereof, selected from the group consisting of oncofetal antigens, MART-1, MAGE-1, MAGS3, gp100, tyrosinase, CEA, PSA, CA-125, erb-3, MUC-1, MUC-2, point-mutated ras, point mutated p53 and TAG-72, said tumor-associated antigen is expressed in cancer, said cancer selected from the group consisting of non-Hodgkin Lymphoma, leukemia, Hodgkins lymphoma, lung cancer, liver cancer, melanoma, adenocarcinoma, thymoma, and sarcoma, and (ii) a second recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein exogenous DNA encoding B7.1, B7.2, or B7.1 and B7.2, wherein tie composition is able to co-infect a host cell resulting in co-expression of the antigen-encoding DNA and the B7.1, B7.2, or B7.1 and B7.2-encoding DNA and further wherein the co-expression causes an enhanced cellular immune response against the cells expressing tumor-associated antigen.

A recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein one or more genes encoding a tumor-associated antigen of a cancer and one or more genes or DNA sequences encoding B7.1, B7.2, or B7.1 and B7.2.

The recombinant virus according to 15 wherein the antigen is carcinoembryonic antigen (CEA).

A recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein exogenous DNA encoding a tumor-associated antigen or immunogenic portion thereof, said antigen selected from the group consisting of oncofetal antigens, MART-1, MAGE-1, MAGE-3, gp100, tyrosinase, CEA, PSA, CA-125, erb-2, Muc-1, Muc-2, point-mutated ras, point-mutated p53 and TAG-72, and exogenous DNA encoding B7.1, B7.2, or B7.1 and B7.2, wherein the virus is able to infect a host cell resulting in co-expression of the antigen-encoding DNA and the B7.1, B7.2, or B7.1 and B7.2-encoding DNA and further wherein the co-expression causes an enhanced cellular immune response against the cells expressing tumor-associated antigen.

A recombinant virus comprising a recombinant virus genome, or an infectable portion thereof, having incorporated therein exogenous DNA encoding a tumor-associated antigen or immunogenic portion thereof, said antigen selected from the group consisting of carcinoembryonic antigen (CEA), prostate specific antigen (PSA) and MUC-1, and exogenous DNA encoding B7.1, B7.2, or B7.1 and B7.2, wherein the virus is able to infect a host cell resulting in co-expression of the antigen-encoding DNA and the B7.1, B7.2 or B7.1 and B7.2-encoding DNA and further wherein the co-expression causes an enhanced cellular immune response against cells expressing CEA, PSA, MUC-1 or immunogenic portion thereof.